Bausch + Lomb Corporation (NYSE:BLCO) Receives $15.60 Consensus Price Target from Brokerages

Shares of Bausch + Lomb Corporation (NYSE:BLCO) have earned a consensus recommendation of “Hold” from the thirteen research firms that are currently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12-month target price among brokers that have covered the stock in the last year is $15.70.

Several brokerages have issued reports on BLCO. Evercore ISI raised their price target on Bausch + Lomb from $16.50 to $17.00 and gave the company an “outperform” rating in a report on Tuesday, October 7th. The Goldman Sachs Group began coverage on Bausch + Lomb in a report on Wednesday, October 1st. They set a “neutral” rating and a $16.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bausch + Lomb in a report on Wednesday, October 8th. Zacks Research raised Bausch + Lomb to a “hold” rating in a report on Tuesday, August 12th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Bausch + Lomb in a report on Tuesday, October 7th.

Institutional Investors Weigh In On Bausch + Lomb

Hedge funds and other institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. lifted its holdings in shares of Bausch + Lomb by 428.7% during the first quarter. Goldman Sachs Group Inc. now owns 299,671 shares of the company’s stock worth $4,345,000 after buying an additional 242,993 shares in the last quarter. Allianz Asset Management GmbH acquired a new stake in shares of Bausch + Lomb during the first quarter worth $4,712,000. Vident Advisory LLC acquired a new stake in shares of Bausch + Lomb during the first quarter worth $289,000. Clearline Capital LP lifted its holdings in shares of Bausch + Lomb by 38.2% during the first quarter. Clearline Capital LP now owns 893,790 shares of the company’s stock worth $12,960,000 after buying an additional 247,149 shares in the last quarter. Finally, Nexpoint Asset Management L.P. lifted its holdings in shares of Bausch + Lomb by 147.6% during the first quarter. Nexpoint Asset Management L.P. now owns 50,158 shares of the company’s stock worth $727,000 after buying an additional 29,900 shares in the last quarter. Institutional investors and hedge funds own 11.07% of the company’s stock.

Bausch + Lomb Price Performance

NYSE:BLCO opened at $14.87 on Tuesday. Bausch + Lomb has a 1-year low of $10.45 and a 1-year high of $21.69. The company has a current ratio of 1.55, a quick ratio of 0.98 and a debt-to-equity ratio of 0.76. The firm has a fifty day simple moving average of $14.70 and a 200 day simple moving average of $13.30. The stock has a market capitalization of $5.27 billion, a PE ratio of -19.06, a P/E/G ratio of 1.57 and a beta of 0.63.

Bausch + Lomb (NYSE:BLCO) last released its earnings results on Wednesday, July 30th. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.01. Bausch + Lomb had a negative net margin of 5.58% and a positive return on equity of 2.33%. The business had revenue of $1.28 billion during the quarter, compared to analysts’ expectations of $1.25 billion. During the same period last year, the business earned $0.13 earnings per share. The firm’s revenue was up 5.1% on a year-over-year basis. Bausch + Lomb has set its FY 2025 guidance at EPS. On average, research analysts expect that Bausch + Lomb will post 0.74 EPS for the current fiscal year.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.